KMWM
ABBV icon

Keudell/Morrison Wealth Management’s AbbVie ABBV Stock Holding History

Keudell/Morrison Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.05M Buy
20,064
+48
+0.2% +$10.3K 0.95% 22
2026
Q1 		$4.35M Buy
20,016
+53
+0.3% +$11.8K 0.89% 24
2025
Q4 		$4.56M Buy
+19,963
New +$4.55M 0.96% 21
2025
Q2 		$3.97M Sell
21,412
-565
-3% -$105K 0.88% 21
2025
Q1 		$4.6M Buy
21,977
+143
+0.7% +$27.8K 1.09% 18
2024
Q4 		$3.88M Buy
21,834
+325
+2% +$59.8K 1.01% 20
2024
Q3 		$4.25M Sell
21,509
-793
-4% -$148K 1.15% 17
2024
Q2 		$3.83M Sell
22,302
-266
-1% -$44.1K 1.12% 18
2024
Q1 		$4.11M Sell
22,568
-1,376
-6% -$237K 1.24% 17
2023
Q4 		$3.71M Sell
23,944
-530
-2% -$77.3K 1.22% 16
2023
Q3 		$3.65M Sell
24,474
-524
-2% -$76.9K 1.11% 19
2023
Q2 		$3.37M Sell
24,998
-883
-3% -$129K 0.97% 19
2023
Q1 		$4.12M Sell
25,881
-376
-1% -$57.5K 1.21% 15
2022
Q4 		$4.24M Sell
26,257
-385
-1% -$59K 1.36% 12
2022
Q3 		$3.58M Sell
26,642
-362
-1% -$51.9K 1.34% 13
2022
Q2 		$4.14M Sell
27,004
-2,165
-7% -$331K 1.5% 11
2022
Q1 		$4.73M Sell
29,169
-784
-3% -$114K 1.98% 7
2021
Q4 		$4.06M Sell
29,953
-764
-2% -$90.2K 1.6% 9
2021
Q3 		$3.31M Buy
30,717
+1,469
+5% +$168K 1.42% 10
2021
Q2 		$3.29M Buy
29,248
+338
+1% +$38.1K 1.8% 10
2021
Q1 		$3.13M Buy
28,910
+1,905
+7% +$204K 1.82% 11
2020
Q4 		$2.89M Sell
27,005
-399
-1% -$38.3K 1.84% 10
2020
Q3 		$2.4M Sell
27,404
-531
-2% -$50K 1.54% 12
2020
Q2 		$2.74M Buy
27,935
+1,144
+4% +$101K 2.27% 5
2020
Q1 		$2.04M Buy
26,791
+1,273
+5% +$108K 2% 7
2019
Q4 		$2.26M Buy
25,518
+415
+2% +$34.5K 1.56% 13
2019
Q3 		$1.9M Buy
25,103
+1,376
+6% +$94.3K 1.57% 15
2019
Q2 		$1.53M Buy
23,727
+3,873
+20% +$304K 1.34% 18
2019
Q1 		$1.6M Buy
+19,854
New +$1.62M 1.41% 18

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Keudell/Morrison Wealth Management's ABBV Position: Q2 2026 in Review

Keudell/Morrison Wealth Management increased its AbbVie (ABBV) stake by 0.24% in Q2 2026, buying an estimated $10.3K and bringing the position to 20,064 shares worth $5.05M. The position accounts for 0.95% of the portfolio, ranked #22.

Keudell/Morrison Wealth Management first reported a position in ABBV in Q1 2019 and has held it in 29 quarters since. 803 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Keudell/Morrison Wealth Management held 20,064 shares of AbbVie worth $5.05M as of Q2 2026.
  • Keudell/Morrison Wealth Management bought 48 AbbVie shares in Q2 2026, an estimated $10.3K.
  • AbbVie made up 0.95% of Keudell/Morrison Wealth Management's portfolio in Q2 2026, its #22 holding.
  • Keudell/Morrison Wealth Management first reported a position in AbbVie in Q1 2019 and has held it in 29 quarters since.
  • 803 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Keudell/Morrison Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.